Member Info for HotChip

What's truly shocking, confidence wise? You are not making sense...

Q122 was what I understood from a recent interview.

You have a lot of thoughts... :)

You should be top-slicing in my opinion. Don't be over-exposed in any particular stock, its not wise regardless of technicals and fundamentals.

DYOR

I'm not sure the potential is there at all and may be has never been...

DYOR

AIM is extremely high risk, this stock is no exception unfortunately. A money-pit maybe...

DYOR

It's still higher than the placing price of 0.90p though. Your perception probably depends on what price you bought in at....

They have provided information on on when new products will be launched - its next year. Can't be any more specific than that, as they are under development. Is that not good enough for you?

That's a helpful comment...

You should have cashed out or top-sliced at least, at those levels.
Still not too late if you do this now, as still 3 x if you bought in at 6p. What's stopping you? Should always top-slice, say 30%, to manage the risk.
DYOR

I don't think this is likely to happen...

You are not making sense pal; terrible grammar...

You clearly don't care, which is fine as its your opinion. But there are also many others that do care, so I guess like most things, opinion is split. I like the idea of moving the whole thing to NASDAQ; far more value and upside imo.
DYOR

Yes, I see that. But what are you suggesting?

I reckon the SP will stay in the range of 21-25 for the remainder of this year, supported by further contracts for clinical trials. When we get news on further dividend species, which we should be expecting during Q122, then I think the SP will start to move upwards again. For the next 2-3 months though, its a case of sit tight, stop viewing the SP and go and do other trades instead and leave this one well alone. This is just my opinion...

DYOR

I guess your opinion on SP performance depends on what you bought in at and what you plan to sell at. If you bought in the single digits or lower teens, then current SP is a great return in a little over a year. If you bought in higher, then not so good.

£21.9m revenue in H121, a 242% increase vs. H120. How does this translate into a 'sham outfit' StrictlyZinc? I assume you can do better?

Very interesting comments indeed....:)
This sounds VERY exciting :)

Very good RNS - clear and to the point. Lots of cash coming in - will be interesting to see H1 results and then year end which I think will be very strong. DYOR

PCR was always temporary; outbound testing will be here for a while yet.

MHC was successful in pivoting during the pandemic and has clear plans to move forward with its core DNA and RNA tests as planned...